Sedative News and Research RSS Feed - Sedative News and Research

A sedative is a substance that induces sedation by reducing irritability or excitement.
Low doses of fluoxetine could hold key to preventing PMS symptoms

Low doses of fluoxetine could hold key to preventing PMS symptoms

Low doses of fluoxetine - better known as the anti-depressant Prozac - could hold the key to preventing PMS symptoms, an international team of researchers has found. [More]
Orexo announces positive results from ISTART/006 study

Orexo announces positive results from ISTART/006 study

Orexo US, Inc. announced results from the ISTART/006 study, being presented today at the 25th Annual Meeting and Symposium of the American Academy of Addiction Psychiatry in Aventura, Florida, USA. [More]
Power grid failure inside injured cardiac cells triggers post-heart attack arrhythmias

Power grid failure inside injured cardiac cells triggers post-heart attack arrhythmias

Heart attack survivors often experience dangerous heart rhythm disturbances during treatment designed to restore blood flow to the injured heart muscle, a common and confounding complication of an otherwise lifesaving intervention. [More]
Large-scale study results of cardiac arrest cases now available on ScienceDirect

Large-scale study results of cardiac arrest cases now available on ScienceDirect

The results of a four-year international study of 2060 cardiac arrest cases across 15 hospitals published and available now on ScienceDirect. [More]
Study: Benzodiazepine sedatives may increase death risk in patients receiving mechanical ventilation

Study: Benzodiazepine sedatives may increase death risk in patients receiving mechanical ventilation

Sedation is frequently required for mechanically ventilated intensive care unit (ICU) patients to reduce anxiety, provide comfort, and assist in providing optimal respiratory support. [More]
AAN releases new position statement on opioids for chronic non-cancer pain

AAN releases new position statement on opioids for chronic non-cancer pain

According to a new position statement from the American Academy of Neurology, the risk of death, overdose, addiction or serious side effects with prescription opioids outweigh the benefits in chronic, non-cancer conditions such as headache, fibromyalgia and chronic low back pain. [More]
Now, women experiencing morning sickness can benefit from Diclegis drug

Now, women experiencing morning sickness can benefit from Diclegis drug

Up to 85 percent of pregnant women are affected by nausea and vomiting of pregnancy (NVP), more commonly known as morning sickness. [More]
FDA approves BELSOMRA® (suvorexant) for the treatment of insomnia

FDA approves BELSOMRA® (suvorexant) for the treatment of insomnia

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved BELSOMRA® (suvorexant) for adults with insomnia who have difficulty falling asleep and/or staying asleep. BELSOMRA (pronounced bell-SOM-rah) is a highly selective antagonist for orexin receptors. [More]
Research highlights widespread use of sleeping medication use among astronauts

Research highlights widespread use of sleeping medication use among astronauts

In an extensive study of sleep monitoring and sleeping pill use in astronauts, researchers from Brigham and Women's Hospital (BWH) Division of Sleep and Circadian Disorders, Harvard Medical School, and the University of Colorado found that astronauts suffer considerable sleep deficiency in the weeks leading up to and during space flight. [More]
New study finds highest rates of decline in prescription drug misuse nationwide

New study finds highest rates of decline in prescription drug misuse nationwide

Five states that have implemented multi-faceted prescription drug abuse prevention programs in recent years showed the highest rate of decline in prescription drug misuse rates nationwide, according to a new study issued today by Quest Diagnostics, the world's leading provider of diagnostic information services. [More]
State highlights: N.C. lawmakers reach Medicaid agreement; Idaho asks SCOTUS to take up Medicaid reimbursement

State highlights: N.C. lawmakers reach Medicaid agreement; Idaho asks SCOTUS to take up Medicaid reimbursement

For the past few weeks, two big issues have kept the two chambers of the General Assembly from reaching an agreement on next year's state budget: teacher salaries and Medicaid. But on Wednesday, the Senate and the House of Representatives finally moved closer to agreement on their Medicaid forecasts, loosening a logjam that's kept legislators in Raleigh past July 1, the beginning of the fiscal year (Hoban, 7/3). [More]
Jazz Pharmaceuticals' JZP-110 improves symptoms of EDS in adults with narcolepsy

Jazz Pharmaceuticals' JZP-110 improves symptoms of EDS in adults with narcolepsy

Jazz Pharmaceuticals plc today presented data from the Phase 2b study evaluating JZP-110 (formerly known as ADX-N05) as a potential new treatment for the symptoms of excessive daytime sleepiness (EDS) in adults with narcolepsy. [More]
Orexo US partners with inVentiv Health to market Zubsolv sublingual tablets in the US

Orexo US partners with inVentiv Health to market Zubsolv sublingual tablets in the US

Orexo AB announces a new partnership between Orexo US, Inc. and inVentiv Health for the commercialization of Zubsolv in the US. [More]
Young adult social drinkers may develop alcohol use disorder over time

Young adult social drinkers may develop alcohol use disorder over time

Heavy social drinkers who report greater stimulation and reward from alcohol are more likely to develop alcohol use disorder over time, report researchers from the University of Chicago, May 15 in the journal Biological Psychiatry. [More]
Researchers identify target molecules for development of new allergy drugs

Researchers identify target molecules for development of new allergy drugs

Researchers have identified several target molecules which are suitable for the development of new allergy drugs. The Journal of Allergy and Clinical Immunology, the most prestigious journal in the field of allergology, has recently published an extensive review article on the prospects of drug therapy for allergy. Completed in a large-scale EU project, the lead author of the review article is Professor Ilkka Harvima of the University of Eastern Finland and Kuopio University Hospital. [More]
Researchers identify several target molecules suitable for development of new allergy drugs

Researchers identify several target molecules suitable for development of new allergy drugs

Researchers have identified several target molecules which are suitable for the development of new allergy drugs. The Journal of Allergy and Clinical Immunology, the most prestigious journal in the field of allergology, has recently published an extensive review article on the prospects of drug therapy for allergy. [More]
New Colombia Resources, Phoenix Tears Foundation to develop cannabis-based medicine for skin cancer

New Colombia Resources, Phoenix Tears Foundation to develop cannabis-based medicine for skin cancer

New Colombia Resources, Inc., a U.S. company with coal and other resource assets in Colombia, is pleased to announce an agreement of collaboration with the Phoenix Tears Foundation for the research and development of a cannabis based medicine to treat skin cancer in Colombia. [More]
Two sedative drugs effectively treat prolonged seizures in children

Two sedative drugs effectively treat prolonged seizures in children

The sedative drugs diazepam (Valium) and lorazepam (Ativan) are equally effective in treating the prolonged seizures known as status epilepticus in children, according to a randomized, controlled study by a multi-institution team of researchers with the Pediatric Emergency Care Applied Research Network, including an expert from the Perelman School of Medicine at the University of Pennsylvania. [More]
Merck's NOXAFIL injection gets FDA approval for intravenous use

Merck's NOXAFIL injection gets FDA approval for intravenous use

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use. [More]
Orexo signs multi-year agreement with OptumRx and UnitedHealth Group

Orexo signs multi-year agreement with OptumRx and UnitedHealth Group

Orexo AB, the manufacturer of ZUBSOLV® (buprenorphine and naloxone) sublingual tablets (CIII), announced a multi-year agreement with UnitedHealth Group® and OptumRx® providing preferred coverage and reimbursement of ZUBSOLV®. [More]